MAV-RAPA: Prospective evaluation of the efficacy of sirolimus (Rapamune) in the treatment of superficial arteriovenous malformations.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516001-23-00

Enrollment

Registered

2025-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficial arteriovenous malformations

Brief summary

the proportion of patients with a reduction in tumour volume of the 30% reduction in AVM tumour volume by angioscannographic criteria during the first year of the study

Detailed description

Assessment of treatment efficacy at three months, six months, nine months

Interventions

DRUGRapamune 1 mg coated tablets

DRUGSOLUPRED 20 mg

DRUGcomprimé orodispersible

DRUGSOLUPRED 5 mg

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the proportion of patients with a reduction in tumour volume of the 30% reduction in AVM tumour volume by angioscannographic criteria during the first year of the study	—

Secondary

Measure	Time frame
Assessment of treatment efficacy at three months, six months, nine months	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026